Utah Medical Products, Inc. (UTMD)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 24/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.21% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Utah Medical Products, Inc. Clarifies Tender Offer Expiration Date
- Utah Medical Products, Inc. Commences Tender Offer
- Utah Medical Products Inc's Dividend Analysis
- Femcare Ltd Acquires Orion Medical Supplies Ltd in the UK
- Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses
- UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2026
- Utah Medical Products, Inc. Announces Quarterly Dividend
- Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2026
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Utah Medical Products, Inc..
Full UTMD Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.